tiprankstipranks
Advertisement
Advertisement

PCJENAV Stock Latest News

JenaValve Highlights Early U.S. Commercial Use of Trilogy TAVR System
Private CompaniesJenaValve Highlights Early U.S. Commercial Use of Trilogy TAVR System
23h ago
JENAV
JenaValve Highlights Early U.S. Commercial Use of Trilogy TAVR for Aortic Regurgitation
PremiumPrivate Companies
JenaValve Highlights Early U.S. Commercial Use of Trilogy TAVR for Aortic Regurgitation
1d ago
JENAV
JenaValve’s Trilogy TAVR System Begins U.S. Commercial Use for Aortic Regurgitation
PremiumPrivate Companies
JenaValve’s Trilogy TAVR System Begins U.S. Commercial Use for Aortic Regurgitation
2d ago
JENAV
JenaValve Marks Initial U.S. Commercial Use of Trilogy TAVR System for Aortic Regurgitation
PremiumPrivate Companies
JenaValve Marks Initial U.S. Commercial Use of Trilogy TAVR System for Aortic Regurgitation
2d ago
JENAV
Early U.S. Commercial Use of Trilogy System Signals Initial Uptake in Aortic Regurgitation Market
PremiumPrivate Companies
Early U.S. Commercial Use of Trilogy System Signals Initial Uptake in Aortic Regurgitation Market
3d ago
JENAV
Early U.S. Commercial Use of JenaValve Trilogy System Signals Initial Market Uptake
PremiumPrivate CompaniesEarly U.S. Commercial Use of JenaValve Trilogy System Signals Initial Market Uptake
3d ago
JENAV
JenaValve Marks U.S. Commercial Launch of Trilogy TAVR System
Premium
Private Companies
JenaValve Marks U.S. Commercial Launch of Trilogy TAVR System
10d ago
JENAV
FDA-Cleared Trilogy System Puts JenaValve in Focus at Major Cardiology Meeting
Premium
Private Companies
FDA-Cleared Trilogy System Puts JenaValve in Focus at Major Cardiology Meeting
15d ago
JENAV
JenaValve Highlights FDA-Approved Trilogy System for Aortic Regurgitation at ACC26
PremiumPrivate Companies
JenaValve Highlights FDA-Approved Trilogy System for Aortic Regurgitation at ACC26
15d ago
JENAV
JenaValve Highlights FDA-Approved Trilogy System for High-Risk Aortic Regurgitation
PremiumPrivate Companies
JenaValve Highlights FDA-Approved Trilogy System for High-Risk Aortic Regurgitation
19d ago
JENAV
JenaValve Highlights Trilogy TAVR Therapy for High-Risk Aortic Regurgitation
PremiumPrivate Companies
JenaValve Highlights Trilogy TAVR Therapy for High-Risk Aortic Regurgitation
19d ago
JENAV
JenaValve Gains FDA Approval for Trilogy Transcatheter Valve for Aortic Regurgitation
PremiumPrivate Companies
JenaValve Gains FDA Approval for Trilogy Transcatheter Valve for Aortic Regurgitation
24d ago
JENAV
FDA Approval of Trilogy Transcatheter Valve Signals Potential Growth Opportunity for JenaValve
PremiumPrivate CompaniesFDA Approval of Trilogy Transcatheter Valve Signals Potential Growth Opportunity for JenaValve
24d ago
JENAV
JenaValve Gains FDA Clearance for Trilogy Transcatheter Valve Targeting Severe Aortic Regurgitation
Premium
Private Companies
JenaValve Gains FDA Clearance for Trilogy Transcatheter Valve Targeting Severe Aortic Regurgitation
24d ago
JENAV
Regulatory Milestone Positions JenaValve’s Trilogy Valve for U.S. Market Entry
Premium
Private Companies
Regulatory Milestone Positions JenaValve’s Trilogy Valve for U.S. Market Entry
24d ago
JENAV
JenaValve Highlights Focus on Aortic Regurgitation and TAVR at CRT2026
PremiumPrivate Companies
JenaValve Highlights Focus on Aortic Regurgitation and TAVR at CRT2026
1M ago
JENAV
Conference Engagement Underscores JenaValve Focus on Aortic Regurgitation and TAVR
PremiumPrivate Companies
Conference Engagement Underscores JenaValve Focus on Aortic Regurgitation and TAVR
1M ago
JENAV
JenaValve Targets Structural Heart Visibility With Presence at CRT 2026
PremiumPrivate Companies
JenaValve Targets Structural Heart Visibility With Presence at CRT 2026
1M ago
JENAV
JenaValve Targets Visibility at CRT 2026 Cardiovascular Conference
PremiumPrivate Companies
JenaValve Targets Visibility at CRT 2026 Cardiovascular Conference
1M ago
JENAV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >